Medicx Health’s MX#™ Named One of the Most Innovative Products of 2022 by PM360

Patent-pending ID Resolution technology offers a significant improvement in reach and resolution to brand eligible patients, including those with rare diseases and cancers.

December 19, 2022 — Scottsdale, AZ — Medicx Health, a proven leader in ID resolution, audience design, campaign activation, and measurement analytics for the life sciences industry, today announced that its newly launched deterministic cookieless ID Resolution technology, MX#™, has been named as one of the most innovative products of 2022 by PM360.

Medicx developed MX# because current and emerging media and patient-level ID Resolution methodologies reliant on first party data are not yielding satisfactory results for programmatic and omnichannel marketing. While Google Chrome isn’t set to deprecate third-party cookies until 2024, other popular browsers like Safari, Firefox, and Edge already block third-party tracking by default. Combined, these browsers represent more than 26% of internet users as of November 2022. That growing gap is a tremendous lost opportunity for pharmaceutical brand reach.

“The entire team at Medicx is honored to be recognized for our innovation by PM360,” commented Medicx CEO, Michael Weintraub. “The recognition reinforces our belief that MX# can drive marketing programs that yield better script performance and ultimately better health outcomes. With our focus exclusively on life sciences, Medicx goes to extraordinary lengths to ensure that privacy and safety compliance is paramount in our execution.”

MX#’s patent-pending processes hone reach and engagement of brand eligible patients and the HCPs who treat them. Unlike probabilistic ID resolution options that rely on volumes of aggregated data, look-alike audiences, or publisher opt-in requirements, MX# taps into Medicx’ vast warehouse of consumer preference data and matches them to real-world evidence including medical and prescription claims, aggregated to hyper local geography groups based on our Micro-Neighborhood® patented targeting technology. The combined platform optimizes audience quality and brand impact.

MX# was selected as part of PM360’s 11th Annual Innovations Issue published each December. This issue was established to serve as a guide to the year’s most innovative Companies, Startups, Divisions, Products, Services, and Strategies from within the healthcare and life sciences industries. PM360 received hundreds of submissions from across the healthcare and life sciences industries. The editorial staff of PM360 evaluated each submission and selected their picks for the most innovative, regardless of category. Ultimately, 46 total innovations were featured in the issue. Within the Product category, a total of 16 products were featured.

About Medicx Founded in 2006, Medicx is a leading omnichannel marketing and analytics company. Trusted by over 61 pharmaceutical manufacturers, 154 brands, and over 35 world-class media agencies, Medicx uses patented geo-targeting and HIPAA compliant deterministic ID resolution technologies to improve ROI on digital advertising programs. Our solutions for pharmaceutical campaign planning, execution, measurement, and optimization maximize brand impact by connecting the entire customer journey with an omnichannel engaged experience.

Count on data-driven creative & maximum engagement performance

Trust our experience and domain expertise in the area of pharmaceutical omni-channel marketing.

It’s complicated, but it doesn’t have to be. Let’s talk about how Medicx can help solve your challenge.

Get in touch →